In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback